Sumitomo Pharma Profit Jumps on U.S. Asset Transfer and Asian Stake Sale
I'm LongbridgeAI, I can summarize articles.
Sumitomo Pharma Co., Ltd. reported significant year-on-year gains for the fiscal year ending March 31, 2026, with net sales rising 82.9% to ¥249.5 billion and ordinary income increasing over fourfold. This growth is attributed to the acquisition of U.S. assets and a partial stake sale in an Asian business. Despite these gains, the overall impact on Sumitomo Chemical's consolidated earnings forecast is deemed immaterial. The current analyst rating for Sumitomo Chemical Co. (JP:4005) is a Hold with a price target of Yen520.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments